CL2022000102A1 - Derivados de 6,7-dihidro-5h-pirido[2,3-c]piridazin-8-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos. - Google Patents

Derivados de 6,7-dihidro-5h-pirido[2,3-c]piridazin-8-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos.

Info

Publication number
CL2022000102A1
CL2022000102A1 CL2022000102A CL2022000102A CL2022000102A1 CL 2022000102 A1 CL2022000102 A1 CL 2022000102A1 CL 2022000102 A CL2022000102 A CL 2022000102A CL 2022000102 A CL2022000102 A CL 2022000102A CL 2022000102 A1 CL2022000102 A1 CL 2022000102A1
Authority
CL
Chile
Prior art keywords
pyridazin
pyrido
dihydro
derivatives
pharmaceutical compositions
Prior art date
Application number
CL2022000102A
Other languages
English (en)
Inventor
Attila Paczal
András Kotschy
James Edward Paul Davidson
Maïa Chanrion
Ana Leticia Maragno
James Brooke Murray
Simon Bedford
Frédéric Colland
Mark Philip Dodsworth
András Herner
Mátyás Pál Timári
Paul Webb
Jérôme-Benoit Starck
Emma Sanders
Tibor Novak
Original Assignee
Servier Lab
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis R&D Ltd filed Critical Servier Lab
Publication of CL2022000102A1 publication Critical patent/CL2022000102A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compuestos de fórmula (I): en donde Het, Het1, Het2, A4, A5, Z1, R1, R2 y R3 son como se definen en la descripción. Medicamentos.
CL2022000102A 2019-07-29 2022-01-13 Derivados de 6,7-dihidro-5h-pirido[2,3-c]piridazin-8-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos. CL2022000102A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19188749 2019-07-29

Publications (1)

Publication Number Publication Date
CL2022000102A1 true CL2022000102A1 (es) 2022-11-04

Family

ID=67514283

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000102A CL2022000102A1 (es) 2019-07-29 2022-01-13 Derivados de 6,7-dihidro-5h-pirido[2,3-c]piridazin-8-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos.

Country Status (29)

Country Link
US (1) US20220363677A1 (es)
EP (1) EP4003989B1 (es)
JP (1) JP2022542595A (es)
KR (1) KR20220041132A (es)
CN (1) CN114450284B (es)
AR (1) AR119494A1 (es)
AU (1) AU2020319652A1 (es)
BR (1) BR112022001373A2 (es)
CA (1) CA3148506A1 (es)
CL (1) CL2022000102A1 (es)
CO (1) CO2022000612A2 (es)
CR (1) CR20220016A (es)
DK (1) DK4003989T3 (es)
FI (1) FI4003989T3 (es)
GE (1) GEP20237581B (es)
HR (1) HRP20240392T1 (es)
IL (1) IL289933A (es)
JO (1) JOP20220010A1 (es)
LT (1) LT4003989T (es)
MA (1) MA56649B1 (es)
MX (1) MX2022001191A (es)
PE (1) PE20220705A1 (es)
PL (1) PL4003989T3 (es)
PT (1) PT4003989T (es)
RS (1) RS65248B1 (es)
SI (1) SI4003989T1 (es)
TW (1) TWI751629B (es)
UY (1) UY38810A (es)
WO (1) WO2021018858A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3684767B1 (en) 2017-09-22 2024-04-24 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
FI3697785T3 (fi) 2017-10-18 2023-04-03 Jubilant Epipad LLC Imidatsopyridiiniyhdisteitä pad:n estäjinä
CN111386265A (zh) 2017-11-06 2020-07-07 朱比连特普罗德尔有限责任公司 作为pd1/pd-l1活化的抑制剂的嘧啶衍生物
IL274762B2 (en) 2017-11-24 2023-10-01 Jubilant Episcribe Llc Novel heterocyclic compounds as PRMT5 inhibitors
KR20200131845A (ko) 2018-03-13 2020-11-24 주빌런트 프로델 엘엘씨 Pd1/pd-l1 상호작용/활성화 억제제로서의 비사이클릭 화합물
CA3198996A1 (en) * 2020-11-24 2022-06-02 Matthew T. Burger Bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
CA3206906A1 (en) * 2021-02-02 2022-08-11 Andras Herner Selective bcl-xl protac compounds and methods of use
CN114181039A (zh) * 2021-12-23 2022-03-15 凯美克(上海)医药科技有限公司 一种4,4-二苯基-3-丁烯-1-醇的合成方法
WO2023225336A1 (en) 2022-05-20 2023-11-23 Novartis Ag Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
WO2023225320A1 (en) 2022-05-20 2023-11-23 Novartis Ag Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
TW202408588A (zh) 2022-05-20 2024-03-01 瑞士商諾華公司 抗體-藥物結合物抗腫瘤化合物及其使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010080503A1 (en) * 2008-12-19 2010-07-15 Genentech, Inc. Heterocyclic compounds and methods of use
US8889675B2 (en) * 2011-10-14 2014-11-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI571466B (zh) * 2011-10-14 2017-02-21 艾伯維有限公司 用於治療癌症及免疫與自體免疫疾病之細胞凋亡誘發劑
TW201414737A (zh) * 2012-07-13 2014-04-16 必治妥美雅史谷比公司 作爲激酶抑制劑之咪唑并三□甲腈
FR3015483B1 (fr) 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2017214233A1 (en) * 2016-06-08 2017-12-14 Abbvie Inc. Anti-egfr antibody drug conjugates
WO2019037678A1 (zh) * 2017-08-24 2019-02-28 上海迪诺医药科技有限公司 吡唑并[3,4-d]嘧啶-3-酮衍生物、其药物组合物及应用

Also Published As

Publication number Publication date
IL289933A (en) 2022-03-01
LT4003989T (lt) 2024-02-12
TWI751629B (zh) 2022-01-01
PE20220705A1 (es) 2022-05-04
CO2022000612A2 (es) 2022-01-28
PT4003989T (pt) 2024-01-30
JOP20220010A1 (ar) 2023-01-30
BR112022001373A2 (pt) 2022-06-07
AU2020319652A1 (en) 2022-02-10
CN114450284B (zh) 2024-05-07
MA56649B1 (fr) 2024-02-29
TW202118764A (zh) 2021-05-16
SI4003989T1 (sl) 2024-04-30
EP4003989A1 (en) 2022-06-01
CR20220016A (es) 2022-03-02
KR20220041132A (ko) 2022-03-31
AR119494A1 (es) 2021-12-22
GEP20237581B (en) 2023-12-25
CA3148506A1 (en) 2021-02-04
US20220363677A1 (en) 2022-11-17
CN114450284A (zh) 2022-05-06
MX2022001191A (es) 2022-02-22
RS65248B1 (sr) 2024-03-29
WO2021018858A1 (en) 2021-02-04
HRP20240392T1 (hr) 2024-06-07
EP4003989B1 (en) 2023-12-27
UY38810A (es) 2021-02-26
DK4003989T3 (da) 2024-03-25
FI4003989T3 (fi) 2024-03-21
PL4003989T3 (pl) 2024-04-29
JP2022542595A (ja) 2022-10-05

Similar Documents

Publication Publication Date Title
CL2022000102A1 (es) Derivados de 6,7-dihidro-5h-pirido[2,3-c]piridazin-8-ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos.
UY38809A (es) Derivados de 3,6-diamino-piridazin-3ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos
UY29795A1 (es) Derivados de adenina, composiciones farmacéuticas que los contienen, procesos de preparación y aplicaciones
UY30493A1 (es) Compuestos derivados 5-cloro-1??h,3h-espiro[ 1-benzofuran-2, 4??- piperidin]-1??-ilo sustituidos de los acidos acético y 2-metil- propanoico, composiciones farmacéuticas, procedimientos de preparacion y aplicaciones
ECSP10010419A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos-211
UY29767A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
CL2019000169A1 (es) Derivados de piperidina.
UY29732A1 (es) Derivados de benzotiazolonas, procesos de preparación, composiciones y combinaciones que los contienen y aplicaciones
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
UY32286A (es) Nuevos derivados de pirrolidindiona espiroheterocíclica n-oxiamida
UY29486A1 (es) Compuestos utiles en terapia
FR3041640B1 (fr) NOUVEAUX DERIVES DE PYRROLO[2,3-d]PYRIMIDINE, LEUR PROCEDE DE PREPRATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT
UY30127A1 (es) Derivados de acidos antranilicos fenoxi y feniltio, composiciones farmaceuticas que los contienen y su uso.
UY29768A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
IN2015DN00538A (es)
ECSP10010664A (es) Derivados de urea heterocíclicos para el tratamiento de infecciones bacterianas
DOP2018000083A (es) NUEVOS DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
CL2020001817A1 (es) Moduladores del receptor c5a
UY32856A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos
UY28356A1 (es) Derivados de benzimidazol, composiciones que los contienen, preparaciones de los mismos y sus usos
ECSP088603A (es) Nuevas n-(fluor-pirazinil)-fenilsulfonamidas como moduladores del receptor de quimioquina ccr4
PH12018502733A1 (en) [1,2,3]triazolo[4,5-d]pyrimidine derivatives with affinity for the type-2 cannabinoid receptor
CO2021004553A2 (es) Nuevos derivados amino-pirimidonil-piperidinilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
AR108389A2 (es) Derivados de ácido fenilacético
CL2020001073A1 (es) Nuevos derivados macrocíclicos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen.